• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为副作用,艾司氯胺酮是否存在渴望和成瘾潜力?

Craving and addictive potential of esketamine as side effects?

机构信息

Unit of Clinical Psychiatry, Department of Clinical Neurosciences/DIMSC, School of Medicine, Polytechnic University of Marche, Ancona, Italy.

出版信息

Expert Opin Drug Saf. 2022 Jun;21(6):803-812. doi: 10.1080/14740338.2022.2071422. Epub 2022 May 4.

DOI:10.1080/14740338.2022.2071422
PMID:35509224
Abstract

INTRODUCTION

Esketamine was approved for adults with treatment-resistant depression (TRD) in conjunction with an oral antidepressant, and for treating depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. However, evidence of great efficacy and safety of esketamine is accompanied by a widespread concern regarding its addictive potential.

AREAS COVERED

A comprehensive review on the craving and addictive potential of ketamine and esketamine was carried out. In addition, a clinical case of a 34-year-old TRD woman treated with esketamine who experienced drug-seeking behaviors and craving symptomatology was described and critically discussed, with a particular focus on treatment strategies to manage craving in the short- and long term.

EXPERT OPINION

Esketamine showed great efficacy and safety in treating TRD and MDD with acute suicidal ideation or behavior. Our clinical experience demonstrated the presence of an additive potential, which has been favorably managed with slow esketamine de-titration and combination with bupropion. However, literature so far published is scant and shows contradictory findings. Therefore, it is crucial to promptly detect and manage craving symptomatology in esketamine-treated TRD patients. In our experience, the use of bupropion to counteract craving and addictive symptoms was proven to be effective and safe.

摘要

简介

氯胺酮与口服抗抑郁药联合用于治疗成人难治性抑郁症(TRD),以及用于治疗伴有急性自杀意念或行为的成人重性抑郁障碍的抑郁症状。然而,氯胺酮具有显著疗效和安全性的同时,也引发了人们对其潜在成瘾性的广泛关注。

涵盖领域

对氯胺酮和 Esketamine 的成瘾性和潜在成瘾性进行了全面的综述。此外,还描述并批判性地讨论了一例接受 Esketamine 治疗的 34 岁 TRD 女性患者出现觅药行为和渴求症状的临床病例,特别关注了短期和长期管理渴求的治疗策略。

专家意见

Esketamine 在治疗 TRD 和伴有急性自杀意念或行为的 MDD 方面显示出了很好的疗效和安全性。我们的临床经验表明存在附加的潜在风险,通过缓慢降低 Esketamine 的剂量并与安非他酮联合使用,可以很好地管理这种风险。然而,到目前为止,已发表的文献很少,且结果相互矛盾。因此,及时发现和管理接受 Esketamine 治疗的 TRD 患者的渴求症状至关重要。根据我们的经验,使用安非他酮来对抗渴求症状和成瘾症状被证明是有效和安全的。

相似文献

1
Craving and addictive potential of esketamine as side effects?作为副作用,艾司氯胺酮是否存在渴望和成瘾潜力?
Expert Opin Drug Saf. 2022 Jun;21(6):803-812. doi: 10.1080/14740338.2022.2071422. Epub 2022 May 4.
2
Esketamine: A Novel Option for Treatment-Resistant Depression.氯胺酮:治疗抵抗性抑郁症的新选择。
Ann Pharmacother. 2020 Jun;54(6):567-576. doi: 10.1177/1060028019892644. Epub 2019 Dec 4.
3
Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.鼻腔内给予 Esketamine 治疗重性抑郁障碍的疗效和安全性。
Expert Opin Pharmacother. 2020 Jan;21(1):9-20. doi: 10.1080/14656566.2019.1683161. Epub 2019 Oct 30.
4
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.治疗抵抗性抑郁症合并物质使用障碍患者中的依他佐辛:REAL-ESK 研究中患者亚组的安全性和有效性观点。
Eur Neuropsychopharmacol. 2023 Sep;74:15-21. doi: 10.1016/j.euroneuro.2023.04.011. Epub 2023 May 4.
5
The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial.依他佐辛治疗伴有自杀意念的重性抑郁障碍的疗效和安全性:一项随机对照试验的研究方案。
BMC Psychiatry. 2022 Nov 30;22(1):744. doi: 10.1186/s12888-022-04388-y.
6
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.依他佐辛鼻喷剂联合口服抗抑郁药治疗治疗抵抗性抑郁症患者预防复发的疗效:一项随机临床试验。
JAMA Psychiatry. 2019 Sep 1;76(9):893-903. doi: 10.1001/jamapsychiatry.2019.1189.
7
Efficacy and Tolerability of Two Novel "Standard of Care" Treatments-Intranasal Esketamine Versus Intravenous Ketamine-for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study.两种新型“标准治疗”方案——鼻内给予艾司氯胺酮与静脉给予氯胺酮——在自然临床实践中治疗难治性抑郁症的疗效和耐受性:一项初步观察性研究方案
JMIR Res Protoc. 2022 May 23;11(5):e34711. doi: 10.2196/34711.
8
A Systematic Review on Ketamine and Esketamine for Treatment-Resistant Depression and Suicidality in Adolescents: A New Hope?氯胺酮和艾司氯胺酮治疗青少年难治性抑郁症和自杀倾向的系统评价:新希望?
Children (Basel). 2024 Jun 29;11(7):801. doi: 10.3390/children11070801.
9
Esketamine for treatment resistant depression.艾氯胺酮用于治疗难治性抑郁症。
Expert Rev Neurother. 2019 Oct;19(10):899-911. doi: 10.1080/14737175.2019.1640604. Epub 2019 Jul 16.
10
The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review.氯胺酮和艾司氯胺酮鼻内制剂治疗重度抑郁症的疗效与安全性:一项系统评价
Pharmaceutics. 2023 Dec 13;15(12):2773. doi: 10.3390/pharmaceutics15122773.

引用本文的文献

1
Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee.在一组接受急性治疗疗程以管理难治性抑郁症的患者中艾氯胺酮的滥用可能性:一项真实世界临床实践中观察性研究的二次分析
Ther Adv Drug Saf. 2025 Jun 19;16:20420986251347360. doi: 10.1177/20420986251347360. eCollection 2025.
2
Effects of Remimazolam Tosilate Combined with Esketamine on Anesthetic Efficacy and Psychiatric Symptoms in Patients Undergoing Ambulatory Surgery: A Randomized Controlled Study.甲苯磺酸瑞马唑仑联合艾司氯胺酮对门诊手术患者麻醉效果及精神症状的影响:一项随机对照研究
Drug Des Devel Ther. 2025 May 30;19:4527-4535. doi: 10.2147/DDDT.S519732. eCollection 2025.
3
Is there a risk of esketamine misuse in clinical practice?在临床实践中,艾氯胺酮存在被滥用的风险吗?
Ther Adv Drug Saf. 2025 Jan 29;16:20420986241310685. doi: 10.1177/20420986241310685. eCollection 2025.
4
Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review.关于艾氯胺酮用于难治性抑郁症治疗的事实与误解:一项叙述性临床综述
Front Psychiatry. 2024 May 15;15:1394787. doi: 10.3389/fpsyt.2024.1394787. eCollection 2024.
5
Synthesis and bioactivity of psilocybin analogues containing a stable carbon-phosphorus bond.含稳定碳-磷键的裸盖菇素类似物的合成与生物活性
RSC Med Chem. 2024 Feb 21;15(3):998-1002. doi: 10.1039/d4md00043a. eCollection 2024 Mar 20.
6
Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada.氯胺酮用于难治性抑郁症的治疗:文献综述更新及在加拿大艾伯塔省埃德蒙顿市一个社区氯胺酮项目中的实际应用
Front Psychiatry. 2024 Jan 8;14:1283733. doi: 10.3389/fpsyt.2023.1283733. eCollection 2023.
7
Thrifty effect of subanesthetic-dose S-ketamine on postoperative opioids and its safety and analgesic effectiveness: A prospective, triple-blind, randomized controlled, polycentric clinical trial.亚麻醉剂量S-氯胺酮对术后阿片类药物的节俭效应及其安全性和镇痛效果:一项前瞻性、三盲、随机对照、多中心临床试验。
Ibrain. 2023 May 15;9(2):171-182. doi: 10.1002/ibra.12104. eCollection 2023 Summer.